Skip to main content
main-content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Ophthalmology 1/2018

Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients

Corneal endothelium after dexamethasone implant injection

Zeitschrift:
BMC Ophthalmology > Ausgabe 1/2018
Autoren:
Hatice Ayhan Güler, Nurgül Örnek, Kemal Örnek, Nesrin Büyüktortop Gökçınar, Tevfik Oğurel, Mehmet Erhan Yumuşak, Zafer Onaran

Abstract

Background

To assess corneal endothelial cell changes after intravitreal dexamethasone (DEX) implant (Ozurdex®) injection in patients with macular edema secondary to retinal vein occlusion (RVO).

Methods

Twenty-two eyes of 22 patients were assessed prospectively after intravitreal 0.7 mg DEX implant injection. Twenty-two eyes of 22 healthy volunteers served as control group. Corneal endothelial cell parameters including endothelial cell density (ECD), coefficient of variation of cell size (CV), percentage of hexagonality (Hex) and central corneal thickness (CCT) were analyzed before and 1 and 3 months after injection by specular microscopy. The results of the study were compared statistically.

Results

There were 17 (77.3%) patients with branch RVO and 5 (22.7%) patients with central RVO. Mean intraocular pressure (IOP) was 14.73 mmHg before injection, 17.05 mmHg at 1 month and 17.15 mmHg at 3 months after injection. Mean IOP at 1 and 3 months were significantly higher than pre-injection value (p = 0.002 and p = 0.003, respectively). There was a statistically significant reduction in mean ECD at 3 months after injection compared to pre-injection and 1 month (p = 0.013, p = 0.009, respectively) in the injected eyes. Mean ECD showed no significant difference in the uninjected fellow eyes during the follow up (p>0.05). Mean CV and Hex did not reveal a statistically significant difference in injected and uninjected fellow eyes (p > 0.05). No significant change was observed in mean CCT values during the follow up (p = 0.8).

Conclusion

Intravitreal dexamethasone implant may cause a transient reduction in corneal endothelial cell density in short term without changing cell morphology.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Ophthalmology 1/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

06.08.2019 | Leitthema | Ausgabe 9/2019

Forschungs- und Entwicklungsbedarf in der Augenheilkunde („Unmet needs“)

Ein konsensbasierter Fahrplan des European Vision Institute (EVI) für die Jahre 2019 bis 2025

01.08.2019 | Erkrankungen der Hornhaut | CME | Ausgabe 8/2019

Neurotrophe Keratopathie

Grundlagen, Diagnostik und Therapie

22.07.2019 | DFP-Fortbildung | Ausgabe 4/2019 Open Access

Aktuelle Möglichkeiten der visuellen Rehabilitation